{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:07:09Z","timestamp":1790759229842,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T00:00:00Z","timestamp":1695686400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072095"],"award-info":[{"award-number":["82072095"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.heliyon.2023.e20474","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T11:57:41Z","timestamp":1695815861000},"page":"e20474","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic potential of single-nucleotide polymorphism-mediated interleukin-6 receptor blockade in cancer treatment: A Mendelian randomization study"],"prefix":"10.1016","volume":"9","author":[{"given":"Shuwan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanxue","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4418-6444","authenticated-orcid":false,"given":"Rui","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9010-4551","authenticated-orcid":false,"given":"Qingjie","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2023.e20474_bib1","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.heliyon.2023.e20474_bib2","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/eurpub\/ckz216","article-title":"Cancer statistics: a comparison between World health organization (WHO) and global burden of disease (GBD)","volume":"30","author":"Mattiuzzi","year":"2020","journal-title":"Eur J Public Health"},{"key":"10.1016\/j.heliyon.2023.e20474_bib3","first-page":"409","article-title":"Cancer treatment and survivorship statistics, 2022","volume":"72","author":"Miller","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.heliyon.2023.e20474_bib4","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.addr.2018.08.005","article-title":"Aptamer-based targeted therapy","volume":"134","author":"Zhu","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.heliyon.2023.e20474_bib5","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.smim.2014.01.001","article-title":"IL-6 and related cytokines as the critical lynchpins between inflammation and cancer","volume":"26","author":"Taniguchi","year":"2014","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.heliyon.2023.e20474_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.760971","article-title":"IL-6\/STAT3 is a promising therapeutic target for hepatocellular carcinoma","volume":"11","author":"Xu","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.heliyon.2023.e20474_bib7","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1038\/sj.onc.1205440","article-title":"N-myc oncogene overexpression down-regulates IL-6; evidence that IL-6 inhibits angiogenesis and suppresses neuroblastoma tumor growth","volume":"21","author":"Hatzi","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.heliyon.2023.e20474_bib8","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1158\/0008-5472.CAN-17-2268","article-title":"IL-6 mediates cross-talk between tumor cells and activated fibroblasts in the tumor microenvironment","volume":"78","author":"Karakasheva","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.heliyon.2023.e20474_bib9","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2023.e20474_bib10","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/nature12873","article-title":"Genetics of rheumatoid arthritis contributes to biology and drug discovery","volume":"506","author":"Okada","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2023.e20474_bib11","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1093\/rheumatology\/keab047","article-title":"Paediatric rheumatology INternational trials organisation (PRINTO) and the paediatric rheumatology collaborative study group (PRCSG), subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis","volume":"60","author":"Ruperto","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.heliyon.2023.e20474_bib12","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s10067-017-3568-y","article-title":"Multicentric Castleman's disease associated with IgA vasculitis (Henoch-Sch\u00f6nlein purpura) responding well to tocilizumab: a case report","volume":"36","author":"Oshima","year":"2017","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.heliyon.2023.e20474_bib13","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/gepi.21758","article-title":"Mendelian randomization analysis with multiple genetic variants using summarized data","volume":"37","author":"Burgess","year":"2013","journal-title":"Genet. Epidemiol."},{"key":"10.1016\/j.heliyon.2023.e20474_bib14","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1111\/bcp.15191","article-title":"Dissecting the IL-6 pathway in cardiometabolic disease: a Mendelian randomization study on both IL6 and IL6R","volume":"88","author":"Cupido","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.heliyon.2023.e20474_bib15","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nmeth.1974","article-title":"1000 genomes project consortium, the 1000 genomes project: data management and community access","volume":"9","author":"Clarke","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.heliyon.2023.e20474_bib16","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.023277","article-title":"Additive effects of genetic interleukin-6 signaling downregulation and low-density lipoprotein cholesterol lowering on cardiovascular disease: a 2\u00d72 factorial mendelian randomization analysis","volume":"11","author":"Georgakis","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.heliyon.2023.e20474_bib17","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.34408","article-title":"The MR-Base platform supports systematic causal inference across the human phenome","volume":"7","author":"Hemani","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.heliyon.2023.e20474_bib18","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/ije\/dyv080","article-title":"Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression","volume":"44","author":"Bowden","year":"2015","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.heliyon.2023.e20474_bib19","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/gepi.21965","article-title":"Consistent estimation in mendelian randomization with some invalid instruments using a weighted median estimator","volume":"40","author":"Bowden","year":"2016","journal-title":"Genet. Epidemiol."},{"key":"10.1016\/j.heliyon.2023.e20474_bib20","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41588-018-0099-7","article-title":"Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases","volume":"50","author":"Verbanck","year":"2018","journal-title":"Nat. Genet."},{"key":"10.1016\/j.heliyon.2023.e20474_bib21","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1093\/ije\/dyx102","article-title":"Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption","volume":"46","author":"Hartwig","year":"2017","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.heliyon.2023.e20474_bib22","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/ije\/dyq151","article-title":"Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants","volume":"40","author":"Pierce","year":"2011","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.heliyon.2023.e20474_bib23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ajhg.2016.11.007","article-title":"Genome-wide association study identifies 27 loci influencing concentrations of circulating cytokines and growth factors","volume":"100","author":"Ahola-Olli","year":"2017","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.heliyon.2023.e20474_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006706","article-title":"Mapping of 79 loci for 83 plasma protein biomarkers in cardiovascular disease","volume":"13","author":"Folkersen","year":"2017","journal-title":"PLoS Genet."},{"key":"10.1016\/j.heliyon.2023.e20474_bib25","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.bbadis.2014.05.018","article-title":"The interleukin-6 receptor Asp358Ala single nucleotide polymorphism rs2228145 confers increased proteolytic conversion rates by ADAM proteases","volume":"1842","author":"Garbers","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.heliyon.2023.e20474_bib26","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nrc1256","article-title":"Tumour-educated macrophages promote tumour progression and metastasis","volume":"4","author":"Pollard","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.heliyon.2023.e20474_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0165-2478(90)90028-O","article-title":"Interleukin-6: historical background, genetics and biological significance","volume":"24","author":"Wolvekamp","year":"1990","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.heliyon.2023.e20474_bib28","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10555-010-9223-6","article-title":"Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity","volume":"29","author":"DeNardo","year":"2010","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.heliyon.2023.e20474_bib29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","article-title":"Inflammation and cancer: triggers, mechanisms, and consequences","volume":"51","author":"Greten","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.heliyon.2023.e20474_bib30","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41586-022-04847-2","article-title":"cGAS-STING drives the IL-6-dependent survival of chromosomally instable cancers","volume":"607","author":"Hong","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2023.e20474_bib31","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s10495-022-01763-8","article-title":"DNA damage induces STING mediated IL-6-STAT3 survival pathway in triple-negative breast cancer cells and decreased survival of breast cancer patients","volume":"27","author":"Vasiyani","year":"2022","journal-title":"Apoptosis"},{"key":"10.1016\/j.heliyon.2023.e20474_bib32","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ajh.23868","article-title":"A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma","volume":"90","author":"Orlowski","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.heliyon.2023.e20474_bib33","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/bjh.12266","article-title":"A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma","volume":"161","author":"Voorhees","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.heliyon.2023.e20474_bib34","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/s41419-021-04268-5","article-title":"The IL-6R and Bmi-1 axis controls self-renewal and chemoresistance of head and neck cancer stem cells","volume":"12","author":"Herzog","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.heliyon.2023.e20474_bib35","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12943-019-0988-0","article-title":"MCT-1\/miR-34a\/IL-6\/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer","volume":"18","author":"Weng","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.heliyon.2023.e20474_bib36","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1053\/j.gastro.2014.08.039","article-title":"Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells","volume":"147","author":"Wan","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.heliyon.2023.e20474_bib37","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10067-012-2114-1","article-title":"Nodular progression of lentigo malignant melanoma during a treatment with tocilizumab: cause or coincidence?","volume":"32","author":"Finet","year":"2013","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.heliyon.2023.e20474_bib38","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000213","article-title":"Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab","volume":"2","author":"Rubbert-Roth","year":"2016","journal-title":"RMD Open"},{"key":"10.1016\/j.heliyon.2023.e20474_bib39","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2023.e20474_bib40","doi-asserted-by":"crossref","first-page":"R141","DOI":"10.1186\/ar3455","article-title":"Integrated safety in tocilizumab clinical trials","volume":"13","author":"Schiff","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.heliyon.2023.e20474_bib41","first-page":"1","article-title":"Targeting IL-6 trans-signalling: past, present and future prospects","author":"Rose-John","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.heliyon.2023.e20474_bib42","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4137\/CMAMD.S7371","article-title":"Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis","volume":"5","author":"Ogata","year":"2012","journal-title":"Clin. Med. Insights Arthritis Musculoskelet. Disord."},{"key":"10.1016\/j.heliyon.2023.e20474_bib43","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1002\/cncr.22999","article-title":"Interleukin-6 and its receptor in cancer: implications for translational therapeutics","volume":"110","author":"Hong","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.heliyon.2023.e20474_bib44","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1083\/jcb.120.5.1281","article-title":"Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression","volume":"120","author":"Lu","year":"1993","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.heliyon.2023.e20474_bib45","doi-asserted-by":"crossref","first-page":"9215","DOI":"10.1073\/pnas.89.19.9215","article-title":"Interleukin 6: a fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression","volume":"89","author":"Lu","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.heliyon.2023.e20474_bib46","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nrgastro.2015.150","article-title":"The global burden of IBD: from 2015 to 2025","volume":"12","author":"Kaplan","year":"2015","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.heliyon.2023.e20474_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2021.155690","article-title":"Blocking only the bad side of IL-6 in inflammation and cancer","volume":"148","author":"Rose-John","year":"2021","journal-title":"Cytokine"},{"key":"10.1016\/j.heliyon.2023.e20474_bib48","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1001\/jama.2023.1084","article-title":"Effect of induction therapy with olamkicept vs placebo on clinical response in patients with active ulcerative colitis: a randomized clinical trial","volume":"329","author":"Zhang","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.heliyon.2023.e20474_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004174","article-title":"Therapeutic potential of IL6R blockade for the treatment of sepsis and sepsis-related death: a Mendelian randomisation study","volume":"20","author":"Hamilton","year":"2023","journal-title":"PLoS Med."},{"key":"10.1016\/j.heliyon.2023.e20474_bib50","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.119.002872","article-title":"Interleukin-6 signaling effects on ischemic stroke and other cardiovascular outcomes: a mendelian randomization study","volume":"13","author":"Georgakis","year":"2020","journal-title":"Circ Genom Precis Med"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240584402307682X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240584402307682X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:45:59Z","timestamp":1790757959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240584402307682X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S240584402307682X"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e20474","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic potential of single-nucleotide polymorphism-mediated interleukin-6 receptor blockade in cancer treatment: A Mendelian randomization study","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e20474","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e20474"}}